The investigational therapeutic monoclonal antibodies, caStx1 and caStx2, have been granted orphan drug status for the treatment of Shiga-toxin producing E. Coli (STEC) infections. This designation provides Caprion
Satraplatin has shown promising safety and efficacy as demonstrated by significant improvement in progression-free survival in a study of first-line hormone-refractory prostate cancer (HRPC). The drug is currently
The lead compound, named NVX-144, is part of Novelix’ pipeline of first-in-class small molecule targeted drugs for cancers resistant to standard treatment. Based on preclinical data, Novelix anticipates
The trial is designed to demonstrate that HCT 3012 is superior to placebo and as effective as a competitor in relieving the signs and symptoms of osteoarthritis, whilst
Animal studies conducted to date suggest a single low-volume injection may provide therapeutic levels of drug for one month or more. If the IND is accepted it will
A prior phase Ib study in normal volunteers conducted by DOV evaluated the safety and pharmacokinetics of repeat doses of DOV 21,947. That trial indicated the drug was
The research also provides evidence that the drug candidate RPI-78M modulates the expression of this gene in laboratory assays. RPI-78M is the lead drug candidate of Nutra Pharma’s
Hereditary angioedema (HAE) is a genetic disorder characterized by recurrent attacks of inflammation affecting the extremities (the hands and feet), the face, the abdomen, and the larynx. The
The application seeks to expand the indication for the drug which is currently approved only as a first-line treatment of metastatic colorectal cancer in combination with chemotherapy. The
The drug is currently available in 100, 50, 25 and 12.5mg tablet dosage strengths. The 200mg tablet is a new dosage strength developed by Ivax to create additional
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.